BACKGROUND: Evidence has been presented that gene polymorphisms (PON54 L/M, PON191 Q/R) of paraoxonase are risk factors of coronary heart disease. RESULTS: We determined both PON genotypes in 535 male individuals who were free of vascular disease and in 2249 male subjects who underwent coronary angiography, and analysed the relation of both gene variations to CAD and MI. Both gene polymorphisms were in linkage disequilibrium (P<0.0001). Coronary artery disease: the PON54 gene polymorphism was not associated with an increased risk of CAD. In the total sample and also in younger subjects, an association of the PON191 gene variation with the risk of CAD was not detected when the control group of individuals without coronary heart disease was compared with patients with at least one diseased vessel (verified by coronary angiography). In individuals younger than 62 years, a moderate increase in the relative risk of CAD associated with the PON191 R allele (1.45 (1. 08-1.95); P=0.015) were found, when subjects without vessel disease (verified by coronary angiography) were compared with CAD patients. Myocardial infarction: an association of the PON54 gene variation with MI was not detected when the control group of individuals without coronary heart disease were compared with patients with at least one MI. A marginal increase in the risk of MI associated with the PON54 LL genotype (OR 1.27 (1.05-1.51); P=0.011) were detected when patients without MI but with coronary angiography were compared with MI positive patients. Subgroup analyses of low- and high-risk populations did not reveal any association of both PON gene polymorphisms with CAD or MI. CONCLUSION: The present findings do not strengthen the hypothesis that the paraoxonase gene polymorphisms are independently associated with coronary heart disease indicating that these gene variations are of little usefulness as genetic markers of cardiovascular disease.
BACKGROUND: Evidence has been presented that gene polymorphisms (PON54 L/M, PON191 Q/R) of paraoxonase are risk factors of coronary heart disease. RESULTS: We determined both PON genotypes in 535 male individuals who were free of vascular disease and in 2249 male subjects who underwent coronary angiography, and analysed the relation of both gene variations to CAD and MI. Both gene polymorphisms were in linkage disequilibrium (P<0.0001). Coronary artery disease: the PON54 gene polymorphism was not associated with an increased risk of CAD. In the total sample and also in younger subjects, an association of the PON191 gene variation with the risk of CAD was not detected when the control group of individuals without coronary heart disease was compared with patients with at least one diseased vessel (verified by coronary angiography). In individuals younger than 62 years, a moderate increase in the relative risk of CAD associated with the PON191 R allele (1.45 (1. 08-1.95); P=0.015) were found, when subjects without vessel disease (verified by coronary angiography) were compared with CAD patients. Myocardial infarction: an association of the PON54 gene variation with MI was not detected when the control group of individuals without coronary heart disease were compared with patients with at least one MI. A marginal increase in the risk of MI associated with the PON54 LL genotype (OR 1.27 (1.05-1.51); P=0.011) were detected when patients without MI but with coronary angiography were compared with MI positive patients. Subgroup analyses of low- and high-risk populations did not reveal any association of both PON gene polymorphisms with CAD or MI. CONCLUSION: The present findings do not strengthen the hypothesis that the paraoxonase gene polymorphisms are independently associated with coronary heart disease indicating that these gene variations are of little usefulness as genetic markers of cardiovascular disease.
Authors: Qi Chen; Steven E Reis; Candace M Kammerer; Dennis M McNamara; Richard Holubkov; Barry L Sharaf; George Sopko; Daniel F Pauly; C Noel Bairey Merz; M Ilyas Kamboh Journal: Am J Hum Genet Date: 2002-11-26 Impact factor: 11.025
Authors: L Cozzi; J Campolo; M Parolini; R De Maria; M C Patrosso; A Marocchi; O Parodi; S Penco Journal: Mol Cell Biochem Date: 2012-12-06 Impact factor: 3.396
Authors: Kimberly A Davis; J Allen Crow; Howard W Chambers; Edward C Meek; Janice E Chambers Journal: Environ Health Perspect Date: 2009-03-12 Impact factor: 9.031
Authors: Rakesh S Birjmohun; Menno Vergeer; Erik S G Stroes; Manjinder S Sandhu; Sally L Ricketts; Michael W Tanck; Nicholas J Wareham; J Wouter Jukema; John J P Kastelein; Kay-Tee Khaw; S Matthijs Boekholdt Journal: PLoS One Date: 2009-08-27 Impact factor: 3.240
Authors: Debbie A Lawlor; Ian N M Day; Tom R Gaunt; Lesley J Hinks; Patricia J Briggs; Matthew Kiessling; Nick Timpson; George Davey Smith; Shah Ebrahim Journal: BMC Genet Date: 2004-06-23 Impact factor: 2.797